NCT01256073已完成1 期
An Open-label, Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 6
- 主要终点
- To assess safety and tolerability of repeating dosings of Anti-KIR(1-7F9)
研究概览
简要总结
The trial is a multi-centre, open-label, safety and tolerability extension trial to the IPH2101-101 (previously NN1975-1733) first human dose trial completed with a larger subject pool at an optimal dose level. The trial is conducted in elderly Acute Myeloid Leukemia (AML) patients over the age of 60 years, in complete remission, and who are not eligible for allogeneic stem-cell transplantation. The dose given to the individual patient will be the same as the patient received in the single dose trial IPH2101-101 and 1 mg/kg or 2 mg/kg for the 12 patients in an additional cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
- •Acute myeloid leukaemia (AML) according to WHO Criteria
- •Morphological complete remission (CR) defined according to NCI criteria, or CRi with incomplete platelet count recovery only after 1 or 2 cycles of induction chemotherapy, and at least 1, and maximally 6 cycles of consolidation chemotherapy:
- •Absolute neutrophile count > 1x 109/L
- •Platelets > 80x109/L
- •Independency of blood transfusions
- •Less than 5% blasts in bone-marrow
- •No Auer rods
- •No symptoms of disease
- •Life expectancy > 4 months as judged by the Investigator
- •The patient is > or = 60 years of age but < or = 80 years of age
- •The patient has completed participation in the IPH2101-101(previously NN1975-1733)trial with an acceptable safety profile, as judged by the Investigator or is screened for the additional cohort
- •Time since last dose of chemotherapy at least 30 days and no more than 60 days if the patient did not participate in IPH2101-101 trial before
- •Recovery from acute toxicities of all previous anti-leukaemic therapies
- •KIR-expression on patient NK-cells (ability to bind Anti-KIR(1-7F9)) if the patient did not participate in IPH2101-101 trial before
- •ECOG performance status 0, 1 or 2
- •No major organ dysfunction as judged by the Investigator
- •The patients must have the following clinical laboratory values:
- •Serum creatinine < or = 2 md/dL
- •Total bilirubin < or = 1.5 x the upper limit of normal
- •Asparatate aminotransferase (AST) < 3x the upper limit of normal
排除标准
- •Known or suspected allergy to trial product or related products
- •Previous participation in this trial
- •AML classified as FAB M3 (APL, acute promyelocytic leukaemia) or with good prognosis AML i.e. t(8;21)(q22;q22) or inv(16)(p13q22) or t(16;16)(p13;q22) or their molecular equivalents
- •Eligibility for allogeneic haematopoietic transplantation
- •The patient is currently receiving, or has within the last 4 weeks received other investigational anti-leukemic treatment such as cytokine treatment, except Anti-KIR(1-7F9)
- •The patient has received G-CSF treatment within the last 30 days prior to screening
- •Systemic steroid treatment within the last 4 weeks prior to screening
- •Patient has active autoimmune disease
- •Diagnosis of monoclonal gammopathy
- •Patient has active infectious disease
- •Previous leukaemic CNS involvement
- •Cardiac failure (New York Heart Association [NYHA] grade III-IV)
- •Left ventricular ejection fraction (LVEF) less than 45 % of normal evaluated by ultrasound or isotopic evaluation
- •Severe neurological/psychiatric disorder
- •HIV or chronic hepatitis infection
- •Clinical evidence of an active second malignancy
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
- •Any new medical condition that in the opinion of the Investigator disqualifies the patient for inclusion
研究组 & 干预措施
IPH2101
Experimental
干预措施: IPH2101 (Drug)
结局指标
主要结局
To assess safety and tolerability of repeating dosings of Anti-KIR(1-7F9)
时间窗: every 2 weeks
using the US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)
次要结局
- To assess the pharmacokinetics upon repeated dosing(s)of Anti-KIR(1-7F9)(every 2 weeks)
- To assess the pharmacodynamics upon repeated dosing(s) of Anti-KIR(1-7F9)(every 2 or 4 weeks)
- To assess signs of efficacy of repeated dosing(s) with Anti-KIR(1-7F9)(to date of progression diagnosed or until death)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic SeizuresPartial-Onset or Primary Generalized Tonic-Clonic SeizuresNCT02849626Eisai Inc.180
终止
3 期
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)Geographic AtrophyNCT02745119Hoffmann-La Roche994
已完成
2 期
A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis PatientsOsteoarthritis, KneeNCT03037489Medivir50
已完成
2 期
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)Amyotrophic Lateral SclerosisNCT00931944Knopp Biosciences74
已完成
2 期
Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)Restless Legs SyndromeNCT00498186UCB Pharma295